Occupation or Discipline
AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia
AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals
Over One-Third of Biotechs Face Cash Crunch, EY 2025 Report Finds
biotech; EY report; cash runway; life sciences; capital constraints; biopharma; 2025; macroeconomic uncertainty
Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter
AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases
IPG Health Leads at Cannes Lions 2025 as Real Chemistry and Ogilvy Health Earn Major Awards
Cannes Lions 2025; IPG Health; Real Chemistry; Ogilvy Health; healthcare marketing; agency awards; Health & Wellness Lions; Grand Prix; AREA 23; Vaseline Verified
Gilead Lays Off 36 Employees After Cancelling Oceanside, California Expansion
Gilead Sciences; layoffs; Oceanside; California; biologics; facility expansion; job cuts; biotech industry; co-location; Foster City
UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity
UCB; biologics manufacturing; US expansion; biomanufacturing; biopharmaceutical; investment; jobs; economic impact
Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area
Genentech; Roche; layoffs; South San Francisco; biotech job cuts; Bay Area; AI strategy; WARN filing; pharmaceutical; biotech industry
Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights
ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines
RadNet Acquires See-Mode to Expand AI Ultrasound for Breast and Thyroid Cancer Diagnostics
RadNet; See-Mode Technologies; AI ultrasound; breast cancer; thyroid cancer; DeepHealth; diagnostic imaging; FDA approval; workflow efficiency; acquisition
Struggling Biotechs Face Harsh Market as Funding and Clinical Successes Dry Up in 2025
biotech layoffs; market downturn; funding challenges; clinical trial failures; investor sentiment; M&A slowdown; job cuts; biotech sector